Tsung-Jung Lin1, Chih-Lin Lin, Chaur-Shine Wang, Shu-O Liu, Li-Ying Liao. 1. Division of Gastroenterology, Department of Internal Medicine, Taipei Municipal Jen-Ai Hospital, 5F, No. 52, Lane 240, Guangfu S. Road, Da-an District Taipei City 106, Taiwan, China.
Abstract
AIM: To assess the prevalence of the two mutations, C282Y and H63D of HFE gene, in healthy subjects, patients with chronic hepatitis C (CHC), and patients with nonalcoholic fatty liver disease (NAFLD) in Taiwan and to explore the contribution of the HFE mutation on serum iron stores in CHC and NAFLD groups. METHODS: We examined C282Y and H63D mutations of HFE gene in 125 healthy subjects, 29 patients with CHC, and 33 patients with NAFLD. The serum iron markers, including ferritin, iron, and total iron binding capacity (TIBC), were assessed in all patients. RESULTS: All of the healthy subjects and patients were free from C282Y mutation. The prevalence of H63D heter-ozygosity was 4/125 (3.20%) in healthy subjects, 2/29 (6.90%) in CHC group, and 1/33 (3.03%) in NAFLD group. The healthy subjects showed no significant difference in the prevalence of H63D mutation as compared with the CHC or NAFLD group. Increased serum iron store was found in 34.48% of CHC patients and 36.36% of NAFLD patients. In three patients of H63D heterozygosity, only one CHC patient had increased serum iron store. There was no significant difference in the prevalence of HFE mutations between patients with increased serum iron store and those without in CHC or NAFLD group. CONCLUSION: The HFE mutations may not contribute to iron accumulation in the CHC or NAFLD group even when serum iron overload is observed in more than one-third of these patients in Taiwan.
AIM: To assess the prevalence of the two mutations, C282Y and H63D of HFE gene, in healthy subjects, patients with chronic hepatitis C (CHC), and patients with nonalcoholic fatty liver disease (NAFLD) in Taiwan and to explore the contribution of the HFE mutation on serum iron stores in CHC and NAFLD groups. METHODS: We examined C282Y and H63D mutations of HFE gene in 125 healthy subjects, 29 patients with CHC, and 33 patients with NAFLD. The serum iron markers, including ferritin, iron, and total iron binding capacity (TIBC), were assessed in all patients. RESULTS: All of the healthy subjects and patients were free from C282Y mutation. The prevalence of H63D heter-ozygosity was 4/125 (3.20%) in healthy subjects, 2/29 (6.90%) in CHC group, and 1/33 (3.03%) in NAFLD group. The healthy subjects showed no significant difference in the prevalence of H63D mutation as compared with the CHC or NAFLD group. Increased serum iron store was found in 34.48% of CHCpatients and 36.36% of NAFLD patients. In three patients of H63D heterozygosity, only one CHCpatient had increased serum iron store. There was no significant difference in the prevalence of HFE mutations between patients with increased serum iron store and those without in CHC or NAFLD group. CONCLUSION: The HFE mutations may not contribute to iron accumulation in the CHC or NAFLD group even when serum iron overload is observed in more than one-third of these patients in Taiwan.
Authors: E C Jazwinska; L M Cullen; F Busfield; W R Pyper; S I Webb; L W Powell; C P Morris; T P Walsh Journal: Nat Genet Date: 1996-11 Impact factor: 38.330
Authors: O Riggio; F Montagnese; P Fiore; S Folino; S Giambartolomei; C Gandin; M Merli; I Quinti; N Violante; S Caroli; O Senofonte; L Capocaccia Journal: Am J Gastroenterol Date: 1997-08 Impact factor: 10.864
Authors: Ruben Hernaez; Edwina Yeung; Jeanne M Clark; Kris V Kowdley; Frederick L Brancati; Wen Hong Linda Kao Journal: J Hepatol Date: 2011-02-24 Impact factor: 25.083